Menhaden Fish Oil (Brevoortia patronus)

Menhaden fish oil, derived from Brevoortia patronus, is a marine lipid rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), omega-3 polyunsaturated fatty acids that modulate inflammatory signaling by competing with arachidonic acid in eicosanoid synthesis pathways. Preclinical research suggests it may reduce pro-inflammatory cytokines, support neurological function, and slow tumor progression, though human clinical evidence remains limited.

Origin & History

Menhaden fish oil is derived from the Gulf menhaden fish (Brevoortia patronus), a small oily fish abundant in the Atlantic and Gulf coasts of North America. The oil is extracted through industrial pressing and solvent extraction of whole fish or byproducts, resulting in a marine omega-3 rich oil high in EPA and DHA.

Historical & Cultural Context

No evidence of traditional medicinal use was found in the research. Menhaden fish oil is primarily a modern dietary supplement derived from industrial fishing operations.

Health Benefits

• May reduce inflammation by decreasing pro-inflammatory markers TNF-α and IL-6 (animal evidence only)
• Potential neuroprotective effects against diabetic neuroinflammation and cognitive decline (preliminary rat studies)
• May slow prostate tumor growth in preclinical models (mouse study PMID: 3356068)
• Reduces inflammatory leukotriene B4 synthesis in neutrophils (equine study PMID: 15638272)
• Rapidly incorporates protective omega-3 fatty acids into heart and brain tissues within 1-2 weeks (animal evidence)

How It Works

EPA and DHA from menhaden fish oil competitively inhibit the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes that convert arachidonic acid into pro-inflammatory prostaglandins and leukotrienes, shifting eicosanoid production toward less inflammatory Series-3 prostaglandins and Series-5 leukotrienes. DHA is also a precursor to specialized pro-resolving mediators (SPMs) such as resolvins (RvD1, RvD2) and protectins, which actively resolve inflammation by suppressing NF-κB signaling and reducing TNF-α and IL-6 transcription. In neurological tissue, DHA incorporation into phospholipid membranes stabilizes synaptic membrane fluidity and modulates BDNF expression, potentially protecting against neuroinflammation-induced cognitive decline.

Scientific Research

No human clinical trials were identified for menhaden fish oil specifically. Available evidence comes from animal models including diabetic rats (n=30), tumor-bearing mice (n=24, PMID: 3356068), and horses (n=10, PMID: 15638272), showing anti-inflammatory and potential anti-cancer effects.

Clinical Summary

Current evidence for menhaden fish oil specifically is confined to preclinical animal models; no large randomized controlled trials have been conducted using Brevoortia patronus-derived oil as the isolated intervention in humans. Rat studies have demonstrated reductions in TNF-α and IL-6 in diabetic neuroinflammation models, and mouse xenograft studies report slowed prostate tumor growth compared to control diets, though these findings cannot be directly extrapolated to humans. The broader omega-3 literature supports cardiovascular and anti-inflammatory effects at doses of 1–4 g EPA+DHA per day in humans, providing mechanistic plausibility for menhaden oil's potential benefits given its similar fatty acid profile to other marine oils. Overall, evidence strength for menhaden-specific claims is low, rated preliminary or insufficient for human therapeutic recommendations.

Nutritional Profile

Menhaden fish oil (Brevoortia patronus) is a lipid-rich marine oil with negligible protein, carbohydrate, and fiber content. Primary macronutrient is fat at ~100% of caloric content. Key bioactive compounds include: Omega-3 long-chain polyunsaturated fatty acids (LC-PUFAs) — EPA (eicosapentaenoic acid, 20:5n-3) at approximately 12–18% of total fatty acids and DHA (docosahexaenoic acid, 22:6n-3) at approximately 7–11% of total fatty acids, making menhaden one of the richest commercial sources of combined EPA+DHA (~19–29% total omega-3 LC-PUFAs by weight of oil). DPA (docosapentaenoic acid, 22:5n-3) present at approximately 1–3%. Saturated fatty acids account for approximately 20–25% of total fatty acids, predominantly palmitic acid (16:0) at ~17–20%. Monounsaturated fatty acids comprise approximately 25–30%, with oleic acid (18:1n-9) and palmitoleic acid (16:1n-7) as primary contributors. Fat-soluble vitamins: Vitamin A (retinol) at approximately 500–2,000 IU/g oil depending on processing; Vitamin D3 (cholecalciferol) at approximately 40–100 IU/g oil, though levels vary significantly with refining. Vitamin E (alpha-tocopherol) added as antioxidant stabilizer in commercial preparations, typically 100–500 ppm. Minor bioactive lipids include phospholipids (trace amounts post-refining), sphingolipids, and plasmalogens. Astaxanthin and other carotenoids present in unrefined oil at trace levels (<1 mg/kg). Cholesterol content approximately 300–600 mg/100g oil. Bioavailability notes: EPA and DHA in fish oil are primarily in triglyceride (TG) form, which has comparable but slightly lower bioavailability than phospholipid or re-esterified TG forms; co-ingestion with dietary fat enhances absorption by 30–50%. Oxidative stability is inherently low due to high PUFA content, necessitating antioxidant addition and refrigerated storage to prevent rancidity and loss of bioactive integrity.

Preparation & Dosage

Animal studies used 1-3 g/kg body weight orally in rats, 17-23% dietary incorporation in mice, and 3% by weight in horses. No human dosage data available from clinical studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin E, Coenzyme Q10, Astaxanthin, Curcumin, Alpha-lipoic acid

Safety & Interactions

Menhaden fish oil is generally well-tolerated at typical doses but may cause gastrointestinal side effects including fishy burps, nausea, and loose stools, particularly at doses exceeding 3 g EPA+DHA per day. At high doses (above 3 g/day), omega-3 fatty acids can impair platelet aggregation and prolong bleeding time, creating a clinically relevant interaction with anticoagulants such as warfarin and antiplatelet drugs like clopidogrel, requiring medical supervision. Individuals with fish or shellfish allergies should exercise caution, and those with atrial fibrillation should note that high-dose omega-3 supplementation has been associated with increased AF risk in some large trials (e.g., STRENGTH trial). Pregnant and breastfeeding women are generally advised to consume omega-3s from low-mercury marine sources, but should consult a physician before supplementing, as menhaden oil's specific contaminant testing profile should be verified by manufacturers.